Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving radiation therapy together with pemetrexed may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving whole-brain radiation therapy together with pemetrexed works in treating patients with brain metastases from non-small cell lung cancer.
Checked against the public recordLast updated Jun 23, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Interventions being studied
- Drug: pemetrexed disodium; Radiation: radiation therapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) * Must have evidence of brain metastases by MRI or CT scan PRIOR CONCURRENT THERAPY: * Recovered from prior oncologic or major surgery * Prior resection of all brain metastases or only site of brain metastases allowed provided there is radiologically evaluable intracranial metastases * No prior cranial irradiation, including stereotactic radiosurgery * More than 30 days since prior non-approved or investigational drug * No other concurrent chemotherapy, immunotherapy, hormonal therapy, radiotherapy, surgery, or experimental medications * No single brain metastases or oligometastatic disease amenable to surgical resection or radiosurgery * Relapsed NSCLC with brain metastases allowed * Not a candidate for double-agent or platinum-based chemotherapy * No leptomeningeal metastases * No clinically relevant (defined by physical exam) pleural effusions or ascites that cannot be controlled with drainage or other procedures Inclusion Criteria: * Karnofsky performance status 70-100% OR ≥ 70 years of age * Life expectancy \> 3 months * Absolute neutrophil count (ANC) \> 1,500/mm³ * Platelet count \> 100,000/mm³ * Hemoglobin ≥ 8 g/dL * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 times upper limit of normal (ULN) * Bilirubin ≤ 1.5 times ULN * Creatinine clearance ≥ 45 mL/min * Able to take vitamins, folic acid, and corticosteroids Exclusion Criteria: * Contraindication or intolerance to corticosteroid therapy * Other malignancies within the past 5 years and disease-free OR prognosis is best defined by the NSCLC in the opinion of the attending physician * Pregnant or nursing * Positive pregnancy test * Fertile patients must use effective contraception * HIV positive * Severe hypersensitivity to pemetrexed disodium * Unable to discontinue NSAIDs for ≥ 5 days * History of underlying dementia, Parkinson's disease, or Alzheimer's disease
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Alamance Oncology/Hematology Associates, LLPBurlington, North Carolina
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel HillChapel Hill, North Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 23, 2017. Always confirm current availability with the study team.